Table 3.

PFS and OS univariate Cox regression analyses of the whole series

		First-line PFS			OS
Variable		HR	95% CI	p	HR	95% CI	p
Gender		1.00	0.77–1.29	0.991	1.11	0.84–1.46	0.438
Age at diagnosis		1.02	1.01–1.03	0.001	1.04	1.02–1.05	< 0.001
Age at metastasis		1.02	1.00–1.03	0.003	1.04	1.02–1.05	< 0.001
Age at metastasis > 60 years		1.40	1.07–1.65	0.015	1.76	1.30–2.38	< 0.001
Tumor grade	1	1			1
	2	1.24	0.58–2.66	0.570	0.67	0.31–1.45	0.321
	3	1.37	0.63–3.00	0.426	1.04	0.47–2.28	0.921
pT	1	1			1
	2	0.82	0.18–3.74	0.806	1.27	0.27–6.00	0.764
	3	1.04	0.25–4.21	0.956	1.92	0.47–7.81	0.360
	4	1.31	0.32–5.36	0.706	2.76	0.67–11.39	0.158
Right sided tumor versus other (left sided and rectum)		1.24	0.94–1.61	0.115	1.36	1.03–1.80	0.030
Metastasis site	Liver	1			1
	Other sites	1.11	0.76–1.64	0.579	1.05	0.71–1.57	0.796
	Multiple sites	1.29	0.97–1.70	0.070	1.17	0.88–1.57	0.277
Multiple site versus single site metastases		1.25	0.91.62	0.082	1.16	0.89–1.52	0.274
KRASmutant (exon 2) versus wild-type		1.25	0.97–1.61	0.083	1.32	1.01–1.72	0.039
First-line therapy	Chemotherapy plus bevacizumab	1			1
	Chemotherapy plus anti-EGFR	1.03	0.49–2.13	0.933	1.05	0.45–2.41	0.909
	Chemotherapy alone	1.44	1.09–1.88	0.008	0.91	0.68–1.22	0.544
First-line therapy	Chemotherapy plus bevacizumab versus other	0.71	0.54–0.93	0.012	1.09	0.81–1.45	0.568
Surgical resection of primary tumor (yes versus no)		0.59	0.40-0.88	0.009	0.64	0.42–0.96	0.030
Surgical resection of metastasis (yes versus no)		0.55	0.41–0.72	< 0.001	0.44	0.32–0.59	< 0.001
Local non-surgical treatment of metastasis (yes versus no)		0.60	0.45–0.80	< 0.001	0.47	0.35–0.64	< 0.001